Alpha-1-antitrypsin in pathogenesis of hepatocellular carcinoma

Hepatitis Monthly

Volumn 12, Issue 10 HCC, 2012, Pages 30-36

  Topic, Aleksandra ^a   Ljujic, Mila ^a   Radojkovic, Dragica ^a  

^a UNIVERSITY OF BELGRADE   (Serbia)

Author keywords

Alpha 1 antitrypsin deficiency; Autophagy; Carcinoma; Fucose; Hepatocellular

Indexed keywords

ALPHA 1 ANTITRYPSIN;

ALLELE; ARTICLE; GENE FREQUENCY; GENE MAPPING; GEOGRAPHIC DISTRIBUTION; GEOGRAPHIC INFORMATION SYSTEM; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER INJURY; MATHEMATICAL ANALYSIS; MITOPHAGY; PROTEIN EXPRESSION;

EID: 84871476851     PISSN: 1735143X     EISSN: 17353408     Source Type: Journal    
DOI: 10.5812/hepatmon.7042     Document Type: Article

References (76)

1. Elliott PR, Pei XY, Dafforn TR, Lomas DA. Topography of a 2.0 A structure of alpha1-antitrypsin reveals targets for rational drug design to prevent conformational disease. Protein Sci. 2000;9(7):1274-81.
2. Richards C, Gauldie J, Baumann H. Cytokine control of acute phase protein expression. Eur Cytokine Netw. 1991;2(2):89-98.
3. Schroeder WT, Miller MF, Woo SL, Saunders GF. Chromosomal localization of the human alpha 1-antitrypsin gene (PI) to 14q31-32. Am J Hum Genet. 1985;37(5):868-72.
4. Carrell RW, Lomas DA. Alpha1-antitrypsin deficiency--a model for conformational diseases. N Engl J Med. 2002;346(1):45-53.
5. Cox DW, Billingsley GD, Callahan JW. Aggregation of plasma Z type alpha 1-antitrypsin suggests basic defect for the deficiency. FEBS Lett. 1986;205(2):255-60.
6. Lomas DA, Evans DL, Finch JT, Carrell RW. The mechanism of Z alpha 1-antitrypsin accumulation in the liver. Nature. 1992;357(6379):605-7.
7. Lomas DA, Finch JT, Seyama K, Nukiwa T, Carrell RW. Alpha 1-antitrypsin Siiyama (Ser53-->Phe). Further evidence for intracellular loop-sheet polymerization. J Biol Chem. 1993;268(21):15333-5.
8. Ray S, Mickleborough TD, Brown JL. Comparison of the properties of rare variants of alpha1-proteinase inhibitor expressed in COS-1 cells and assessment of their potential as risk factors in human disease. Biochim Biophys Acta. 2005;1740(3):390-402.
9. Canva V, Piotte S, Aubert JP, Porchet N, Lecomte-Houcke M, Huet G, et al. Heterozygous M3Mmalton alpha1-antitrypsin deficiency associated with end-stage liver disease: case report and review. Clin Chem. 2001;47(8):1490-6.
10. Hidvegi T, Schmidt BZ, Hale P, Perlmutter DH. Accumulation of mutant alpha1-antitrypsin Z in the endoplasmic reticulum activates caspases-4 and -12, NFkappaB, and BAP31 but not the unfolded protein response. J Biol Chem. 2005;280(47):39002-15.
11. Teckman JH, An JK, Loethen S, Perlmutter DH. Fasting in alpha1-antitrypsin deficient liver: constitutive [correction of consultative] activation of autophagy. Am J Physiol Gastrointest Liver Physiol. 2002;283(5):G1156-65.
12. Lawless MW, Mankan AK, Gray SG, Norris S. Endoplasmic reticulum stress--a double edged sword for Z alpha-1 antitrypsin deficiency hepatoxicity. Int J Biochem Cell Biol. 2008;40(8):1403-14.
13. Piitulainen E, Carlson J, Ohlsson K, Sveger T. Alpha1-antitrypsin deficiency in 26-year-old subjects: lung, liver, and protease/protease inhibitor studies. Chest. 2005;128(4):2076-81.
14. Triger DR, Millward-Sadler GH, Czaykowski AA, Trowell J, Wright R. Alpha-1-antitrypsin deficiency and liver in adults. Q J Med. 1976;45(178):B51-72.
15. Rakela J, Goldschmiedt M, Ludwig J. Late manifestation of chronic liver disease in adults with alpha-1-antitrypsin deficiency. Dig Dis Sci. 1987;32(12):1358-62.
16. Berg NO, Eriksson S. Liver disease in adults with alpha-1 -antitrypsin deficiency. N Engl J Med. 1972;287(25):1264-7.
17. Eriksson S. Alpha 1-antitrypsin deficiency and liver cirrhosis in adults. An analysis of 35 Swedish autopsied cases. Acta Med Scand. 1987;221(5):461-7.
18. Hodges JR, Millward-Sadler GH, Barbatis C, Wright R. Heterozygous MZ alpha 1-antitrypsin deficiency in adults with chronic active hepatitis and cryptogenic cirrhosis. N Engl J Med. 1981;304(10):557-60.
19. Graziadei IW, Joseph JJ, Wiesner RH, Therneau TM, Batts KP, Porayko MK. Increased risk of chronic liver failure in adults with heterozygous alpha1-antitrypsin deficiency. Hepatology. 1998;28(4):1058-63.
20. Fischer HP, Ortiz-Pallardo ME, Ko Y, Esch C, Zhou H. Chronic liver disease in heterozygous alpha1-antitrypsin deficiency PiZ. J Hepatol. 2000;33(6):883-92.
21. Regev A, Guaqueta C, Molina EG, Conrad A, Mishra V, Brantly ML, et al. Does the heterozygous state of alpha-1 antitrypsin deficiency have a role in chronic liver diseases? Interim results of a large case-control study. J Pediatr Gastroenterol Nutr. 2006;43(Suppl 1):S30-5.
22. Propst T, Propst A, Dietze O, Judmaier G, Braunsteiner H, Vogel W. High prevalence of viral infection in adults with homozygous and heterozygous alpha 1-antitrypsin deficiency and chronic liver disease. Ann Intern Med. 1992;117(8):641-5.
23. Eigenbrodt ML, McCashland TM, Dy RM, Clark J, Galati J. Heterozygous alpha 1-antitrypsin phenotypes in patients with end stage liver disease. Am J Gastroenterol. 1997;92(4):602-7.
24. Bowlus CL, Willner I, Zern MA, Reuben A, Chen P, Holladay B, et al. Factors associated with advanced liver disease in adults with alpha1-antitrypsin deficiency. Clin Gastroenterol Hepatol. 2005;3(4):390-6.
25. Valenti L, Dongiovanni P, Piperno A, Fracanzani AL, Maggioni M, Rametta R, et al. Alpha 1-antitrypsin mutations in NAFLD: high prevalence and association with altered iron metabolism but not with liver damage. Hepatology. 2006;44(4):857-64.
26. Crowley JJ, Sharp HL, Freier E, Ishak KG, Schow P. Fatal liver disease associated with alpha 1-antitrypsin deficiency PiM1/PiMduarte. Gastroenterology. 1987;93(2):242-4.
27. Chan CH, Steer CJ, Vergalla J, Jones EA. Alpha1-antitrypsin deficiency with cirrhosis associated with the protease inhibitor phenotype SZ. Am J Med. 1978;65(6):978-86.
28. Kok KF, te Morsche RH, van Oijen MG, Drenth JP. Prevalence of genetic polymorphisms in the promoter region of the alpha-1 antitrypsin (SERPINA1) gene in chronic liver disease: a case control study. BMC Gastroenterol. 2010;10:22.
29. Kishimoto Y, Yamada S, Hirayama C. An association between alpha 1-antitrypsin phenotype and chronic liver disease. Hum Genet. 1990;84(2):132-6.
30. Rudnick DA, Perlmutter DH. Alpha-1-antitrypsin deficiency: a new paradigm for hepatocellular carcinoma in genetic liver disease. Hepatology. 2005;42(3):514-21.
31. Rawlings W, Jr., Moss J, Cooper HS, Hamilton SR. Hepatocellular carcinoma and partial deficiency of alpha-1 antitrypsin (MZ). Ann Intern Med. 1974;81(6):771-3.
32. Eriksson S, Hagerstrand I. Cirrhosis and malignant hepatoma in alpha 1-antitrypsin deficiency. Acta Med Scand. 1974;195(6):451-8.
33. Palmer PE, Wolfe HJ. Alpha-antitrypsin deposition in primary hepatic carcinomas. Arch Pathol Lab Med. 1976;100(5):232-6.
34. Reintoft I, Hagerstrand IE. Does the Z gene variant of alpha-1-antitrypsin predispose to hepatic carcinoma? Hum Pathol. 1979;10(4):419-24.
35. Nakopoulou L, Theodoropoulos G, Kotsis L, Papacharalampous N. Demonstration of alpha 1-antitrypsin in paraffin sections of hepatoma and cirrhosis. Virchows Arch A Pathol Anat Histol. 1982;397(2):163-70.
36. Eriksson S, Carlson J, Velez R. Risk of cirrhosis and primary liver cancer in alpha 1-antitrypsin deficiency. N Engl J Med. 1986;314(12):736-9.
37. Elzouki AN, Eriksson S. Risk of hepatobiliary disease in adults with severe alpha 1-antitrypsin deficiency (PiZZ): is chronic viral hepatitis B or C an additional risk factor for cirrhosis and hepatocellular carcinoma? Eur J Gastroenterol Hepatol. 1996;8(10):989-94
38. Propst T, Propst A, Dietze O, Judmaier G, Braunsteiner H, Vogel W. Prevalence of hepatocellular carcinoma in alpha-1-antitrypsin deficiency. J Hepatol. 1994;21(6):1006-11.
39. Zhou H, Ortiz-Pallardo ME, Ko Y, Fischer HP. Is heterozygous alpha-1-antitrypsin deficiency type PIZ a risk factor for primary liver carcinoma? Cancer. 2000;88(12):2668-76.
40. Mihalache F, Hoblinger A, Grunhage F, Krawczyk M, Gartner BC, Acalovschi M, et al. Heterozygosity for the alpha1-antitrypsin Z allele may confer genetic risk of cholangiocarcinoma. Aliment Pharmacol Ther. 2011;33(3):389-94.
41. Govindarajan S, Ashcavai M, Peters RL. alpha-1-Antitrypsin phenotypes in hepatocellular carcinoma. Hepatology. 1981;1(6):628-31.
42. Labadie H, Sesboue R, Martin JP, Beaugrand M. [Hepatocellular carcinoma and the alpha 1-antitrypsin phenotype]. Gastroenterol Clin Biol. 1985;9(12):881-5.
43. Rabinovitz M, Gavaler JS, Kelly RH, Prieto M, Van Thiel DH. Lack of increase in heterozygous alpha 1-antitrypsin deficiency phenotypes among patients with hepatocellular and bile duct carcinoma. Hepatology. 1992;15(3):407-10.
44. Gharib AF, Karam RA, Pasha HF, Radwan MI, Elsawy WH. Polymorphisms of hemochromatosis, and alpha-1 antitrypsin genes in Egyptian HCV patients with and without hepatocellular carcinoma. Gene. 2011;489(2):98-102.
45. Ezzikouri S, El Feydi AE, El Kihal L, Afifi R, Benazzouz M, Hassar M, et al. Prevalence of common HFE and SERPINA1 mutations in patients with hepatocellular carcinoma in a Moroccan population. Arch Med Res. 2008;39(2):236-41.
46. Sherman M. Screening for hepatocellular carcinoma. Best Pract Res Clin Gastroenterol. 2005;19(1):101-18.
47. Lieberman J, Silton RM, Agliozzo CM, McMahon J. Hepatocellular carcinoma and intermediate alpha1-antitrypsin deficiency (MZ phenotype). Am J Clin Pathol. 1975;64(3):304-10.
48. Manekeller S, Sauerbruch T, Fischer HP, Propping P, Hirner A. [Heterozygous alpha-1-antitrypsin deficiency (PiMZ): risk factor in the development of primary liver carcinoma in non-cirrhotic liver?]. Z Gastroenterol. 2010;48(10):1211-4.
49. van den Hazel SJ, Meijer JW, van den Elshout FJ, de Vries RA. [Primary liver cell carcinoma as complication of alpha 1-antitrypsin deficiency in a 67 year old man]. Ned Tijdschr Geneeskd. 2000;144(47):2269-72.
50. Marwick TH, Cooney PT, Kerlin P. Cirrhosis and hepatocellular carcinoma in a patient with heterozygous (MZ) alpha-1-antitrypsin deficiency. Pathology. 1985;17(4):649-52.
51. Theodoropoulos G, Fertakis A, Archimandritis A, Kapordelis C, Angelopoulos B. Alpha 1-antitrypsin phenotypes in cirrhosis and hepatoma. Acta Hepatogastroenterol (Stuttg). 1976;23(2):114-7.
52. Carlson JA, Rogers BB, Sifers RN, Finegold MJ, Clift SM, DeMayo FJ, et al. Accumulation of PiZ alpha 1-antitrypsin causes liver damage in transgenic mice. J Clin Invest. 1989;83(4):1183-90.
53. Marcus NY, Brunt EM, Blomenkamp K, Ali F, Rudnick DA, Ahmad M, et al. Characteristics of hepatocellular carcinoma in a murine model of alpha-1-antitrypsin deficiency. Hepatol Res. 2010;40(6):641-53.
54. Wu Y, Whitman I, Molmenti E, Moore K, Hippenmeyer P, Perlmutter DH. A lag in intracellular degradation of mutant alpha 1-antitrypsin correlates with the liver disease phenotype in homozygous PiZZ alpha 1-antitrypsin deficiency. Proc Natl Acad Sci U S A. 1994;91(19):9014-8.
55. Hidvegi T, Ewing M, Hale P, Dippold C, Beckett C, Kemp C, et al. An autophagy-enhancing drug promotes degradation of mutant alpha1-antitrypsin Z and reduces hepatic fibrosis. Science. 2010;329(5988):229-32.
56. Carroll TP, Greene CM, O'Connor CA, Nolan AM, O'Neill SJ, McElvaney NG. Evidence for unfolded protein response activation in monocytes from individuals with alpha-1 antitrypsin deficiency. J Immunol. 2010;184(8):4538-46.
57. Qu D, Teckman JH, Omura S, Perlmutter DH. Degradation of a mutant secretory protein, alpha1-antitrypsin Z, in the endoplasmic reticulum requires proteasome activity. J Biol Chem. 1996;271(37):22791-5.
58. Kruse KB, Brodsky JL, McCracken AA. Characterization of an ERAD gene as VPS30/ATG6 reveals two alternative and functionally distinct protein quality control pathways: one for soluble Z variant of human alpha-1 proteinase inhibitor (A1PiZ) and another for aggregates of A1PiZ. Mol Biol Cell. 2006;17(1):203-12.
59. Teckman JH, Perlmutter DH. Retention of mutant alpha(1)-antitrypsin Z in endoplasmic reticulum is associated with an autophagic response. Am J Physiol Gastrointest Liver Physiol. 2000;279(5):G961-74.
60. Perlmutter DH. Liver injury in alpha1-antitrypsin deficiency: an aggregated protein induces mitochondrial injury. J Clin Invest. 2002;110(11):1579-83.
61. Teckman JH, An JK, Blomenkamp K, Schmidt B, Perlmutter D. Mitochondrial autophagy and injury in the liver in alpha 1-antitrypsin deficiency. Am J Physiol Gastrointest Liver Physiol. 2004;286(5):G851-62.
62. Varela AS, Lopez Saez JJ. Utility of plasmatic levels of alpha-1-anti?protease (A1AP) as a cancer marker. Cancer Lett. 1995;89(1):15-21.
63. Chen XL, Zhou L, Yang J, Shen FK, Zhao SP, Wang YL. Hepatocellular carcinoma-associated protein markers investigated by MALDI-TOF MS. Mol Med Report. 2010;3(4):589-96.
64. Kew MC, Turnbull R, Prinsloo I. alpha1-Antitrypsin deficiency and hepatocellular cancer. Br J Cancer. 1978;37(4):635-8.
65. Chio LF, Oon CJ. Changes in serum alpha 1 antitrypsin, alpha1 acid glycoprotein and beta 2 glycoprotein I in patients with malignant hepatocellular carcinoma. Cancer. 1979;43(2):596-604.
66. Hong WS, Hong SI. Clinical usefulness of alpha-1-antitrypsin in the diagnosis of hepatocellular carcinoma. J Korean Med Sci. 1991;6(3):206-13.
67. Sawaya R, Zuccarello M, Highsmith R. Alpha-1-antitrypsin in human brain tumors. J Neurosurg. 1987;67(2):258-62.
68. Tzonou A, Sparos L, Kalapothaki V, Zavitsanos X, Rebelakos A, Trichopoulos D. Alpha 1-antitrypsin and survival in hepatocellular carcinoma. Br J Cancer. 1990;61(1):72-3.
69. Pirisi M, Fabris C, Soardo G, Toniutto P, Vitulli D, Bartoli E. Prognostic value of serum alpha-1-antitrypsin in hepatocellular carcinoma. Eur J Cancer. 1996;32A(2):221-5.
70. Lee HB, Yoo OJ, Ham JS, Lee MH. Serum alpha 1-antitrypsin in patients with hepatocellular carcinoma. Clin Chim Acta. 1992;206(3):225-30.
71. Naitoh A, Aoyagi Y, Asakura H. Highly enhanced fucosylation of serum glycoproteins in patients with hepatocellular carcinoma. J Gastroenterol Hepatol. 1999;14(5):436-45.
72. Turner GA, Skillen AW, Buamah P, Guthrie D, Welsh J, Harrison J, et al. Relation between raised concentrations of fucose, sialic acid, and acute phase proteins in serum from patients with cancer: choosing suitable serum glycoprotein markers. J Clin Pathol. 1985;38(5):588-92.
73. Sekine C, Aoyagi Y, Suzuki Y, Ichida F. The reactivity of alpha-1-antitrypsin with Lens culinaris agglutinin and its usefulness in the diagnosis of neoplastic diseases of the liver. Br J Cancer. 1987;56(3):371-5.
74. Carlson J, Eriksson S, Alm R, Kjellstrom T. Biosynthesis of abnormally glycosylated alpha 1-antitrypsin by a human hepatoma cell line. Hepatology. 1984;4(2):235-41.
75. Wang M, Long RE, Comunale MA, Junaidi O, Marrero J, Di Bisceglie AM, et al. Novel fucosylated biomarkers for the early detec?tion of hepatocellular carcinoma. Cancer Epidemiol Biomarkers Prev. 2009;18(6):1914-21.
76. Comunale MA, Rodemich-Betesh L, Hafner J, Wang M, Norton P, Di Bisceglie AM, et al. Linkage specific fucosylation of alpha-1-antitrypsin in liver cirrhosis and cancer patients: implications for a biomarker of hepatocellular carcinoma. PLoS One. 2010;5(8):e12419.